Search Results for: prostate cancer

Health Discovery Corp (HDC) announces that it has entered into an agreement with Abbott to commercialize its new molecular diagnostics gene-based tests for clinically significant prostate cancer.

CombiMatrix Corporation has announced the introduction of the ProScan, which complements the company’s growing portfolio of array-based diagnostic tests.

Common painkillers like aspirin and ibuprofen appear to lower a mans PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.

Health Discovery Corporation has announced that their new gene-based molecular diagnostic test for prostate cancer has now successfully completed its Phase III double-blind clinical trial and is now ready for commercialization. It will be presented at the upcoming Biomarker Discovery Europe 2008 conference in Dublin, Ireland on October 2-3.

Prostate cancer diagnosis tends to be delayed and surgical treatment more difficult in obese men than in lean men, according to two recently published studies.